On 21 May 2015, orphan designation (EU/3/15/1497) was granted by the European Commission to Prana Biotechnology UK Limited, United Kingdom, for 5,7-dichloro-2-dimethylaminomethyl-8-hydroxyquinoline hydrochloride for the treatment of Huntington's disease.

The sponsorship was transferred to Drug Development and Regulation S.L., Spain, in April 2019.

Please note that this product was withdrawn from the Union Register of orphan medicinal products in November 2019 on request of the Sponsor.

Key facts

Active substance
5,7-dichloro-2-dimethylaminomethyl-8-hydroxyquinoline hydrochloride
Disease / condition
Treatment of Huntington’s disease
Date of first decision
EU designation number

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

Drug Development and Regulation S.L.
Consell de Cent 375
Piso 03 01 
Tel. +34 9352 85385

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

How useful was this page?

Add your rating